Cargando…
Fibrostenotic strictures in Crohn’s disease
The use of biologic agents including anti-tumor necrosis factor monoclonal antibodies followed by anti-integrins and anti-interleukins has drastically changed the treatment paradigm of Crohn’s disease (CD) by improving clinical symptoms and mucosal healing. However, up to 70% of CD patients still ev...
Autores principales: | Yoo, Jun Hwan, Holubar, Stefan, Rieder, Florian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Association for the Study of Intestinal Diseases
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609387/ https://www.ncbi.nlm.nih.gov/pubmed/32259917 http://dx.doi.org/10.5217/ir.2019.09148 |
Ejemplares similares
-
Medical Therapy of Fibrostenotic Crohn's Disease
por: Siegmund, Britta
Publicado: (2015) -
Nutritional interventions in adult fibrostenotic Crohn’s disease: A systematic review
por: Cooper, Jared L., et al.
Publicado: (2023) -
A192 EFFICACY OF USTEKINUMAB IN SMALL BOWEL STRICTURES OF FIBROSTENOTIC CROHN'S DISEASE AS ASSESSED BY INTESTINAL ULTRASOUND
por: St-Pierre, J, et al.
Publicado: (2023) -
Worse outcomes and higher costs of care in fibrostenotic Crohn’s disease: a real-world propensity-matched analysis in the USA
por: Dehghan, Melody, et al.
Publicado: (2021) -
Obliterative Muscularization of the Small Bowel Submucosa in Fibrostenotic Crohn's Disease
por: McNeill, Matthew B., et al.
Publicado: (2020)